hotspot -WSS

hotspot

author：leisure time 2025-10-02 22:28:04 - browse：8769

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： How state and local governments are sidelining science

WSS

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Amazon expands telehealth clinic nationwide

Cancer diagnosis changes perspective doctor, former hospital CEO

Experimental asthma app from Apple and Anthem shows promise

Micronoma's microbiome cancer diagnostic approach under fire

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

knowledge

hotspot

focus

After affirmative action ruling, medical educators look to 'holistic review'

Cancer diagnosis changes perspective doctor, former hospital CEO

Alkermes shareholders re

FDA reorg will put new emphasis on investigations, sources say

At least 13 dead in Texas as scorching temps continue

Scientists inch closer to single

Anesthesiologist group: stop taking Ozempic before surgery

Physician groups backed by private equity giant lobby on mergers

As demand for Covid shots wanes, Moderna seeks its next success

A letter from the executive editor: STAT UnitedHealth investigation

Wikipedia

Ventyx halts psoriasis drug development after lackluster trial results

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Vertex non

What is STAT's opinion section for?

What is STAT's opinion section for?

Mega Millions pot grows to $1.25 billion after no winner

hotspot

focus

explore

leisure time